Keith J. Gray’s conviction underscores rising enforcement and audit risk as Medicare spending shifts toward high-cost genetic testing.
A federal jury in Dallas has convicted Texas laboratory owner and former NFL player Keith J. Gray for orchestrating a $328 million Medicare fraud scheme tied to unnecessary cardiovascular genetic testing. Gray, age 39, owned and operated Axis Professional Labs LLC and Kingdom Health Laboratory LLC, which billed Medicare for tests that were not medically necessary, according to the US Department of Justice (DOJ).
The jury convicted Gray on multiple counts, including conspiracy to defraud the United States, violations of the Anti-Kickback Statute, and money laundering. He now faces up to 10 years in prison for each count, with sentencing to be determined by a federal judge.
Gray briefly pursued a professional football career after playing at the University of Connecticut, signing as an undrafted free agent with the Carolina Panthers in 2009 and later spending time on the Indianapolis Colts practice squad, though he never appeared in a regular-season NFL game, according to Fox Sports.
Kickbacks and Sham Contracts Drove Genetic Testing Fraud
According to evidence presented at trial, Gray paid illegal kickbacks to marketers in exchange for Medicare beneficiaries’ DNA samples, personal information, and signed physician orders, the DOJ said. These marketers relied on aggressive telemarketing tactics and a practice known as “doctor chasing,” in which they identified patients’ primary care physicians and pressured them to approve genetic testing orders, prosecutors noted. In many cases, these approvals were based on pre-screening conducted by non-medical personnel rather than legitimate clinical evaluations.
To conceal the scheme, Gray used sham contracts and falsified invoices that were labeled as payments for marketing services, software, or loans. In reality, these payments were structured to match per-sample kickbacks. “Evidence at trial included text messages between Gray and his co-conspirator becoming giddy over the amount of money they were making from Medicare,” the DOJ noted.
Photo credit: NFL Photos
The two laboratories billed Medicare approximately $328 million in fraudulent claims, resulting in about $54 million in payments. Gray used some of these proceeds to purchase luxury vehicles, including high-end trucks and SUVs, as part of efforts to launder the illicit funds.
The case was investigated by multiple federal and state agencies, including the FBI, HHS Office of Inspector General, Texas Medicaid Fraud Control Unit, and the VA Office of Inspector General, underscoring ongoing enforcement efforts targeting fraud in clinical laboratory testing.
The Gray case underscores exactly the risk highlighted in a recent article from The Dark Report on a report from the Department of Health and Human Services’ Office of Inspector General that found genetic tests make up just 5% of volume but now drive 43% of Medicare Part B lab spending. As Medicare spending becomes increasingly concentrated in high-cost genetic testing, enforcement agencies are intensifying scrutiny around medical necessity and billing practices.
Gray’s $328 million fraud scheme—built on kickbacks, questionable ordering practices, and medically unnecessary tests—reflects the same misbehaviors regulators are now targeting. Because of fraud cases such as this, honest laboratories must make greater effort to strengthen compliance, validate ordering patterns, and prepare for heightened audits in the molecular diagnostics space.
Strategies to mitigate diagnostic testing fraud will be a key focus at the 31st Annual Executive War College taking place in New Orleans April 28-29.
—Janette Wider
